Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates
暂无分享,去创建一个
[1] S. Kara,et al. Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children , 2015, Pediatric Drugs.
[2] C. Landersdorfer,et al. Colistin: How should It Be Dosed for the Critically Ill? , 2015, Seminars in Respiratory and Critical Care Medicine.
[3] Brian T. Tsuji,et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. , 2015, The Lancet. Infectious diseases.
[4] S. Rosenbaum,et al. Developmental pharmacokinetics in pediatric populations. , 2014, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
[5] C. Ateş,et al. The Use of Colistin in Critically Ill Children in a Pediatric Intensive Care Unit , 2014, The Pediatric infectious disease journal.
[6] N. Gogtay,et al. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection , 2013, European Journal of Clinical Pharmacology.
[7] A. Apisarnthanarak,et al. Risk Factors and Outcomes of Carbapenem-resistant Acinetobacter baumannii Bacteremia in Neonatal Intensive Care Unit: A Case-case-control Study , 2013, The Pediatric infectious disease journal.
[8] K. Chokephaibulkit,et al. Clinical features, risk factors, and outcome of carbapenem-resistant Acinetobacter baumannii bacteremia in a Thai neonatal intensive care unit , 2012 .
[9] V. Manchanda,et al. Intravenous Colistin Administration in Neonates , 2011, The Pediatric infectious disease journal.
[10] K. Chokephaibulkit,et al. Safety in treatment of ventilator‐associated pneumonia due to extensive drug‐resistant Acinetobacter Baumannii with aerosolized colistin in neonates: A preliminary report , 2011, Pediatric pulmonology.
[11] G. Iotti,et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. , 2010, Chest.
[12] J. Turnidge,et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. , 2010, The Journal of antimicrobial chemotherapy.
[13] Brian T. Tsuji,et al. Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model , 2010, Antimicrobial Agents and Chemotherapy.
[14] J. Turnidge,et al. Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models , 2009, Antimicrobial Agents and Chemotherapy.
[15] P. Tamma,et al. Use of colistin in children. , 2009, The Pediatric infectious disease journal.
[16] A. Armaganidis,et al. Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria , 2009, Antimicrobial Agents and Chemotherapy.
[17] M. Falagas,et al. Intravenous Colistimethate (Colistin) Use in Critically Ill Children Without Cystic Fibrosis , 2009, The Pediatric infectious disease journal.
[18] P. Kiratisin,et al. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[19] J. Turnidge,et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. , 2006, The Lancet. Infectious diseases.
[20] Phillip J. Bergen,et al. Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.
[21] M. Falagas,et al. Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic Fibrosis , 2005, Antimicrobial Agents and Chemotherapy.
[22] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[23] J. Turnidge,et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[24] J. Turnidge,et al. In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis , 2001, Antimicrobial Agents and Chemotherapy.
[25] N. Holford,et al. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. , 2000, British journal of clinical pharmacology.
[26] E. G. Beveridge,et al. Sodium sulphomethyl derivatives of polymyxins. , 1967, British journal of pharmacology and chemotherapy.
[27] W. M. Wallace,et al. Total body water in children. , 1951, Pediatrics.
[28] O. Levy,et al. Immunology of the Fetus and Newborn , 2018 .
[29] Mhairi G. MacDonald MBChB Dch Frcpe Faap,et al. Avery's Neonatology: Pathophysiology and Management of the Newborn , 2015 .